Georges Azzi

Georges Azzi: Medical Doctor MD. Hematology/Oncology

[Christine A. Garcia, MD, MPH @christinemphmd]

New @Nature study: >50% of lung cancer metastases are seeded by other metastases, not the primary tumor. This "seeding from seeding" reveals a complex evolutionary cascade that allows cancer to colonize the body.
https://t.co/lYUyfRYOcP

[SWOG Cancer Research Network @SWOG]

If patients w #MIBC have a clinically sig response to NAT, is cystectomy needed? S2427 BRIGHT trial tests whether pembro + RT can let patients keep their bladder. Systematic biopsies needed at post-NAT TURBT.
Co-PI: Abhishek Tripathi, MD @cityofhope
https://t.co/h6AYneI4Qt

[Sumanta K. Pal, MD, FASCO @montypal]

This is huge. Congrats to @tompowles1 @BartsECMC & team who took this from a brilliant paper in @Nature in 2021 to a paradigm-shifting + P3 trial. @BladderCancerUS @IBCG_BladderCA

[Toni Choueiri, MD @DrChoueiri]

JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers!

@NateraGenetics @tompowles1 @Roche

https://t.co/OlOirNfWHo

[Eric Topol @EricTopol]

The Peptide Craze
I review what we know about 15 different injectable peptides being used without FDA approval or off-label, and NAD+
In the new Ground Truths; free, open-access

[Toni Choueiri, MD @DrChoueiri]

1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author @BraunMDPhD @YaleCancer and #PatrickOtt #DerinKeskin #CatherineWu @DanaFarber

https://t.co/BdbKJqNiE4

@DanaFarber_GU @OncoAlert @DFCI_NeoVax

[Georges Azzi @azzi]

9/9 Stay tuned as these advancements bridge the gap between research and routine care, paving the way for ctDNA to become a gold standard in oncology.

📖 Read the full study in Nature Medicine: https://t.co/db5OBbdsGd

[Georges Azzi @azzi]

🧵 Breakthrough in Early-Stage Lung Adenocarcinoma Recurrence Detection Using ctDNA

[Georges Azzi @azzi]

Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma | Nature Medicine https://t.co/7nHjlbVt1G

[Georges Azzi @azzi]

8/9 In early-stage NSCLC, where recurrence risk is high despite surgery, personalized ctDNA assays like NeXT Personal are essential for precision medicine. This is a giant leap toward better patient outcomes and more efficient trials. 🧬

[Georges Azzi @azzi]

Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma | Nature Medicine https://t.co/7nHjlbVt1G

[Toni Choueiri, MD @DrChoueiri]

Liquid biopsy is here to stay!
Clearance of ctDNA in neoadjuvant phase is associated with improved outcomes to durva + tremlo + EV in cis-ineligible pts with MIBC

# ESMO24
@OncoAlert

[Georges Azzi @azzi]

@DrSteveMartin @n8pennell @JackWestMD @Tony_Calles @StephenVLiu @ADesaiMD @NarjustFlorezMD @lungoncdoc @PatelOncology @christine_lovly @LukasDelasos @DRCamidge Ctdna I assume using liquid biopsy and not MRD level detection at which MAF ?

[Tom Powles @tompowles1]

Building a clinical/genetic ctDNA prognostic model for OS in CRPC #ASCO24 . Including CtDNA improves accuracy compared clinical factors alone. Adding specific AR alterations is even better